Diagnostic Markers in Hepatocellular Carcinoma Using Immunohistochemical Techniques

  • Yaw Ohene-Abuakwa
  • Massimo Pignatelli
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 45)

Abstract

Hepatocellular carcinoma (HCC) is the seventh most common cancer in men and the ninth in women with an estimated incidence of about 1 million per year worldwide. HCC also accounts for 90% of all primary hepatic malignancies, and in most cases, appears to be a consequence of chronic infection of the liver by hepatotropic viruses (hepatitis B and hepatitis C viruses) (1). It is a highly malignant tumor with a poor prognosis that has been attributed to late diagnosis. Detection of HCC at an early stage may result in more effective treatment. However, the lack of symptoms in the early stage of the disease makes screening of patients at risk for HCC impractical. Surgical tumor resection or liver transplantation has been accepted as the only means of cure, but the postoperative recurrence within the remaining liver or even in the transplanted organ is also a cause of poor prognosis (2). It is therefore important to identify factors in tissues that can predict tumor recurrence and prognosis after resection in order to provide adjuvant therapy to different patient groups. It has recently been reported that proliferation rate and markers of cell loss, such as necrosis and apoptosis, may have prognostic value. Proliferation markers such as MIB-1 (Ki-67) and proliferating cell nuclear antigen (PCNA) have been studied in tumor specimens

Keywords

Hepatitis Microwave Sodium Chloride Aldehyde Dehydration 

References

  1. 1.
    Okuda, K. and Okua, H. (1991) Primary liver cell carcinoma, in Oxford Textbook of Clinical Hepathology (McIntyre, N., Benhamou, J. P., Bircher, J., Rizzeto, M., and Rodes, J., eds.), Oxford University Press, Oxford, 1019–1053.Google Scholar
  2. 2.
    Tsai, J. F., Jeng, J. E., Ho, M. S., Chang, W. Y., Lin, Z., Y., and Tsai, J. H. (1995) Clinical evaluation of serum (-foetoprotein and circulating immune complexes as tumor markers of hepatocellular carcinoma. Br. J. Cancer 72, 442–446.CrossRefPubMedGoogle Scholar
  3. 3.
    Tannapfel, A., Geissler, F., Kockerling, F., Katalinic, A., Hauss, J., and Wittekind, C. (1999) Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J. Pathol. 187, 439–445.CrossRefPubMedGoogle Scholar
  4. 4.
    Sherlock, S. and Dooley, J. (1993) Disease of the Liver and Biliary System, Blackwell Scientific, Oxford, 503–531.Google Scholar
  5. 5.
    Borzo, M., Bruno, S., and Roncalli, M. (1991) Liver dysplasia and the risk of hepatocellular carcinoma in cirrhosis: a preliminary report. Br. Med. J. 302, 1312.CrossRefGoogle Scholar
  6. 6.
    Sung, C. H., Hu, C. P., and Hsu, H. C. (1989) Expression of Class I and Class II major histocompatibility antigens on human hepatocellular carcinoma. J. Clin. Invest. 83, 421–429.CrossRefPubMedGoogle Scholar
  7. 7.
    Haglund, C., Lindgren, J., Roberts, P. J., and Nordling, S. (1991) Difference in tissue expression of tumor markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma. Br. J. Cancer. 63, 386–389.CrossRefPubMedGoogle Scholar
  8. 8.
    Sciot, R., Van Eyken, P., and Desmet, V. J. (1990) Transferrin receptor expression in benign tumors and in hepatoblastoma of the liver. Histopathology. 16, 59–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Polak, J. M., and van Noorden, S. (1997) Introduction to Immunocytochemistry, Bios Scientific, Oxford, UK.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Yaw Ohene-Abuakwa
    • 1
  • Massimo Pignatelli
    • 1
  1. 1.Division of Histopathology, Department of Pathology and MicrobiologyUniversity of Bristol, Bristol Royal InfirmaryBristolUK

Personalised recommendations